Product
ALXN1820
Aliases
ALXN1820 IV, ALXN1820 SC
2 clinical trials
2 indications
Indication
HealthyIndication
Sickle Cell DiseaseClinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of Subcutaneous and Intravenous ALXN1820 in Healthy ParticipantsStatus: Completed, Estimated PCD: 2022-09-01
Clinical trial
A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-06-24